A strategy for the generation of specific human antibodies by directed evolution and phage display -: An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom

被引:48
作者
Riaño-Umbarila, L [1 ]
Juárez-González, VR [1 ]
Olamendi-Portugal, T [1 ]
Ortíz-León, M [1 ]
Possani, LD [1 ]
Becerril, B [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca, Morelos, Mexico
关键词
affinity maturation; directed evolution; human scFv library; phage display; scorpion toxin;
D O I
10.1111/j.1742-4658.2005.04687.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study describes the construction of a library of single-chain antibody fragments (scFvs) from a single human donor by individual amplification of all heavy and light variable domains (1.1 x 10(8) recombinants). The library was panned using the phage display technique, which allowed selection of specific scFvs (3F and C1) capable of recognizing Cn2, the major toxic component of Centruroides noxius scorpion venom. The scFv 3F was matured in vitro by three cycles of directed evolution. The use of stringent conditions in the third cycle allowed the selection of several improved clones. The best scFv obtained (6009F) was improved in terms of its affinity by 446-fold, from 183 nm (3F) to 410 pm. This scFv 6009F was able to neutralize 2 LD50 of Cn2 toxin when a 1 : 10 molar ratio of toxin-to-antibody fragment was used. It was also able to neutralize 2 LD50 of the whole venom. These results pave the way for the future generation of recombinant human antivenoms.
引用
收藏
页码:2591 / 2601
页数:11
相关论文
共 49 条
[1]   ISOLATION AND CHARACTERIZATION OF 2 TOXINS FROM THE MEXICAN SCORPION CENTRUROIDES-LIMPIDUS-LIMPIDUS KARSCH [J].
ALAGON, AC ;
GUZMAN, HS ;
MARTIN, BM ;
RAMIREZ, AN ;
CARBONE, E ;
POSSANI, LD .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1988, 89 (01) :153-161
[2]   Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments [J].
Aubrey, N ;
Muzard, J ;
Peter, JC ;
Rochat, H ;
Goyffon, M ;
Devaux, C ;
Billiald, P .
TOXICON, 2004, 43 (03) :233-241
[3]   Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin [J].
Aubrey, N ;
Devaux, C ;
Sizaret, PY ;
Rochat, H ;
Goyffon, M ;
Billiald, P .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (03) :617-628
[4]   Phage display technology: clinical applications and recent innovations [J].
Azzazy, HME ;
Highsmith, WE .
CLINICAL BIOCHEMISTRY, 2002, 35 (06) :425-445
[5]   Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies [J].
Bai, JR ;
Sui, JH ;
Zhu, RY ;
Tallarico, AS ;
Gennari, F ;
Zhang, DS ;
Marasco, WA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1433-1442
[6]   Pharmacokinetics and biodistribution of genetically engineered antibodies [J].
Batra, SK ;
Jain, M ;
Wittel, UA ;
Chauhan, SC ;
Colcher, D .
CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (06) :603-608
[7]   Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity [J].
Boder, ET ;
Midelfort, KS ;
Wittrup, KD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) :10701-10705
[8]   New technologies in therapeutic antibody development [J].
Brekke, OH ;
Loset, GÅ .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (05) :544-550
[9]  
Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28
[10]  
Cardoso DF, 2000, SCAND J IMMUNOL, V51, P337